GRI Bio raises $13.9M in gross proceeds since Jan 2024; cash runway into mid Q1 2025

GRI Bio, Inc.

Closed Oct 22 warrant exercise for 762,236 shares raising $0.8M gross proceeds.
Total gross proceeds since start of 2024 are approximately $13.9M.
Cash runway estimated into mid Q1 2025, supporting Phase 2a interim data for GRI-0621 (IPF).
Issued new Series D-1 and D-2 warrants with exercise price of $1.00 per share.
H.C. Wainwright acted as exclusive placement agent for the offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.